gsk3901961
Cell therapyexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 30, 2020 (NCT04526509)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cancer/testis antigen 1Immunity, passive
Cancer/testis antigen 1 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06048705 | Phase 1 | Mar 9, 2021 | GlaxoSmithKline |
| NCT05943990 | Phase 1 | Dec 21, 2020 | GlaxoSmithKline |
| NCT04526509 | Phase 1 | Oct 30, 2020 | GlaxoSmithKline |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 3 | 1 | 2020 |
1 organizations
Page 1 / 1